ELITEK Rx

Select the drug indication to add to your list

ELITEK

Hyperuricemia
Only 4 drugs may be compared at once

Generic Name and Formulations:

Rasburicase (recombinant) 1.5mg, 7.5mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains mannitol.

Company:

Sanofi Aventis

Select therapeutic use:

Indications for ELITEK:

Single course treatment for initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.

Adults and Children:

Give by IV infusion over 30 mins. 0.2mg/kg daily for 5 days. Dosing >5 days or more than one course of treatment: not recommended.

Contraindications:

History of anaphylaxis, or development of hemolytic reactions or methemoglobinemia to rasburicase. G6PD deficiency.

Warnings/Precautions:

Discontinue permanently if serious hypersensitivity reactions (including anaphylaxis), hemolysis, or methemoglobinemia develops. Screen high risk patients (eg, African or Mediterranean ancestry) for G6PD deficiency prior to initiation. Pregnancy (Cat.C); avoid. Nursing mothers: not recommended.

Interactions:

Interferes with uric acid measurements in blood samples left at room temperature.

Pharmacological Class:

Urate oxidase.

Adverse Reactions:

GI upset, pyrexia, peripheral edema, anxiety, headache, abdominal pain, constipation, hypophosphatemia, hyperbilirubinemia, mucositis, sepsis; anaphylaxis, hemolysis, methemoglobinemia.

Generic Availability:

NO

How Supplied:

Single-use vials 1.5mg—3 (w. diluent); 7.5mg—1 (w. diluent)

ELITEK 1.5mg vials (Qty:1)

appx. price $839.00